313 related articles for article (PubMed ID: 38612768)
1. Protein Arginine Methyltransferases in Pancreatic Ductal Adenocarcinoma: New Molecular Targets for Therapy.
Bhandari K; Ding WQ
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612768
[TBL] [Abstract][Full Text] [Related]
2. Protein arginine methyltransferases (PRMTs): Orchestrators of cancer pathogenesis, immunotherapy dynamics, and drug resistance.
Gao Y; Feng C; Ma J; Yan Q
Biochem Pharmacol; 2024 Mar; 221():116048. PubMed ID: 38346542
[TBL] [Abstract][Full Text] [Related]
3. Promising role of protein arginine methyltransferases in overcoming anti-cancer drug resistance.
Zhu Y; Xia T; Chen DQ; Xiong X; Shi L; Zuo Y; Xiao H; Liu L
Drug Resist Updat; 2024 Jan; 72():101016. PubMed ID: 37980859
[TBL] [Abstract][Full Text] [Related]
4. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibition is synthetically lethal with arginine deprivation in pancreatic cancers with low argininosuccinate synthetase 1 expression.
Kim SS; Xu S; Cui J; Poddar S; Le TM; Hayrapetyan H; Li L; Wu N; Moore AM; Zhou L; Yu AC; Dann AM; Elliott IA; Abt ER; Kim W; Dawson DW; Radu CG; Donahue TR
Theranostics; 2020; 10(2):829-840. PubMed ID: 31903153
[TBL] [Abstract][Full Text] [Related]
6. PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma.
Giuliani V; Miller MA; Liu CY; Hartono SR; Class CA; Bristow CA; Suzuki E; Sanz LA; Gao G; Gay JP; Feng N; Rose JL; Tomihara H; Daniele JR; Peoples MD; Bardenhagen JP; Geck Do MK; Chang QE; Vangamudi B; Vellano C; Ying H; Deem AK; Do KA; Genovese G; Marszalek JR; Kovacs JJ; Kim M; Fleming JB; Guccione E; Viale A; Maitra A; Emilia Di Francesco M; Yap TA; Jones P; Draetta G; Carugo A; Chedin F; Heffernan TP
Nat Commun; 2021 Jul; 12(1):4626. PubMed ID: 34330913
[TBL] [Abstract][Full Text] [Related]
7. Role of epigenetics in pancreatic ductal adenocarcinoma.
Pandey S; Gupta VK; Lavania SP
Epigenomics; 2023 Jan; 15(2):89-110. PubMed ID: 36647796
[TBL] [Abstract][Full Text] [Related]
8. PRMT1 promotes pancreatic cancer growth and predicts poor prognosis.
Song C; Chen T; He L; Ma N; Li JA; Rong YF; Fang Y; Liu M; Xie D; Lou W
Cell Oncol (Dordr); 2020 Feb; 43(1):51-62. PubMed ID: 31520395
[TBL] [Abstract][Full Text] [Related]
9. Arginine Methylation of MDH1 by CARM1 Inhibits Glutamine Metabolism and Suppresses Pancreatic Cancer.
Wang YP; Zhou W; Wang J; Huang X; Zuo Y; Wang TS; Gao X; Xu YY; Zou SW; Liu YB; Cheng JK; Lei QY
Mol Cell; 2016 Nov; 64(4):673-687. PubMed ID: 27840030
[TBL] [Abstract][Full Text] [Related]
10. Arginine metabolism: a potential target in pancreatic cancer therapy.
Yang JS; Wang CC; Qiu JD; Ren B; You L
Chin Med J (Engl); 2020 Nov; 134(1):28-37. PubMed ID: 33395072
[TBL] [Abstract][Full Text] [Related]
11. SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.
Liu E; Zhang ZZ; Cheng X; Liu X; Cheng L
BMC Med Genomics; 2020 Apr; 13(Suppl 5):50. PubMed ID: 32241274
[TBL] [Abstract][Full Text] [Related]
12. Roles of lncRNAs in pancreatic ductal adenocarcinoma: Diagnosis, treatment, and the development of drug resistance.
Jiang XY; Zhu QC; Zhang XJ; Duan T; Feng J; Sui XB; Sun XN; Mou YP
Hepatobiliary Pancreat Dis Int; 2023 Apr; 22(2):128-139. PubMed ID: 36543619
[TBL] [Abstract][Full Text] [Related]
13. Chemoresistance in pancreatic ductal adenocarcinoma: Overcoming resistance to therapy.
Bhoopathi P; Mannangatti P; Das SK; Fisher PB; Emdad L
Adv Cancer Res; 2023; 159():285-341. PubMed ID: 37268399
[TBL] [Abstract][Full Text] [Related]
14. Pooled CRISPR screening in pancreatic cancer cells implicates co-repressor complexes as a cause of multiple drug resistance via regulation of epithelial-to-mesenchymal transition.
Ramaker RC; Hardigan AA; Gordon ER; Wright CA; Myers RM; Cooper SJ
BMC Cancer; 2021 May; 21(1):632. PubMed ID: 34049503
[TBL] [Abstract][Full Text] [Related]
15. NDRG1 overcomes resistance to immunotherapy of pancreatic ductal adenocarcinoma through inhibiting ATG9A-dependent degradation of MHC-1.
Zhang Z; Song B; Wei H; Liu Y; Zhang W; Yang Y; Sun B
Drug Resist Updat; 2024 Mar; 73():101040. PubMed ID: 38228036
[TBL] [Abstract][Full Text] [Related]
16. PRMT1 promotes pancreatic cancer development and resistance to chemotherapy.
Ku B; Eisenbarth D; Baek S; Jeong TK; Kang JG; Hwang D; Noh MG; Choi C; Choi S; Seol T; Kim H; Kim YH; Woo SM; Kong SY; Lim DS
Cell Rep Med; 2024 Mar; 5(3):101461. PubMed ID: 38460517
[TBL] [Abstract][Full Text] [Related]
17. RIOK3 promotes mTORC1 activation by facilitating SLC7A2-mediated arginine uptake in pancreatic ductal adenocarcinoma.
Qin H; Sun R; Guo X; Fang L; Xu M; Teng Y; Zhen N; Wang A; Liu J
Aging (Albany NY); 2023 Feb; 15(4):1039-1051. PubMed ID: 36880835
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
Chandana S; Babiker HM; Mahadevan D
Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
[TBL] [Abstract][Full Text] [Related]
19. Molecular Therapeutics of Pancreatic Ductal Adenocarcinoma: Targeted Pathways and the Role of Cancer Stem Cells.
Stoica AF; Chang CH; Pauklin S
Trends Pharmacol Sci; 2020 Dec; 41(12):977-993. PubMed ID: 33092892
[TBL] [Abstract][Full Text] [Related]
20. TGF-β Inhibitors in Metastatic Pancreatic Ductal Adenocarcinoma.
Alvarez MA; Freitas JP; Mazher Hussain S; Glazer ES
J Gastrointest Cancer; 2019 Jun; 50(2):207-213. PubMed ID: 30891677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
